These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29051829)

  • 21. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
    de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35701185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP; Vermersch P
    Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
    Signori A; Ponzano M; Alexandri N; Giovannoni G; Sormani MP
    Eur J Neurol; 2022 Jul; 29(7):2144-2147. PubMed ID: 35258154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.
    Montalban X; Leist TP; Cohen BA; Moses H; Campbell J; Hicking C; Dangond F
    Neurol Neuroimmunol Neuroinflamm; 2018 Sep; 5(5):e477. PubMed ID: 30027104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Tintore M; Cobo-Calvo A; Carbonell P; Arrambide G; Otero-Romero S; Río J; Tur C; Comabella M; Nos C; Arévalo MJ; Midaglia L; Galán I; Vidal-Jordana A; Castilló J; Rodríguez-Acevedo B; Zabalza de Torres A; Salerno A; Auger C; Sastre-Garriga J; Rovira À; Montalban X
    Neurology; 2021 Oct; 97(17):e1641-e1652. PubMed ID: 34521693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.
    Filippi M; Preziosa P; Meani A; Ciccarelli O; Mesaros S; Rovira A; Frederiksen J; Enzinger C; Barkhof F; Gasperini C; Brownlee W; Drulovic J; Montalban X; Cramer SP; Pichler A; Hagens M; Ruggieri S; Martinelli V; Miszkiel K; Tintorè M; Comi G; Dekker I; Uitdehaag B; Dujmovic-Basuroski I; Rocca MA
    Lancet Neurol; 2018 Feb; 17(2):133-142. PubMed ID: 29275979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy.
    Wiendl H; Schmierer K; Hodgkinson S; Derfuss T; Chan A; Sellebjerg F; Achiron A; Montalban X; Prat A; De Stefano N; Barkhof F; Leocani L; Vermersch P; Chudecka A; Mwape C; Holmberg KH; Boschert U; Roy S;
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers.
    Stuve O; Soelberg Soerensen P; Leist T; Giovannoni G; Hyvert Y; Damian D; Dangond F; Boschert U
    Ther Adv Neurol Disord; 2019; 12():1756286419854986. PubMed ID: 31244898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M
    Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update.
    Jack D; Damian D; Nolting A; Galazka A
    Mult Scler Relat Disord; 2021 Jun; 51():102929. PubMed ID: 33813097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    De Stefano N; Giorgio A; Battaglini M; De Leucio A; Hicking C; Dangond F; Giovannoni G; Sormani MP
    Mult Scler; 2018 Feb; 24(2):222-226. PubMed ID: 28140753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
    Giovannoni G; Coyle PK; Vermersch P; Walker B; Aldridge J; Nolting A; Galazka A; Lemieux C; Leist TP
    Front Immunol; 2021; 12():763433. PubMed ID: 35003076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials.
    Moccia M; Lanzillo R; Petruzzo M; Nozzolillo A; De Angelis M; Carotenuto A; Palladino R; Brescia Morra V
    Front Neurol; 2020; 11():489. PubMed ID: 32625161
    [No Abstract]   [Full Text] [Related]  

  • 35. Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria.
    Habek M; Pavičić T; Ruška B; Pavlović I; Gabelić T; Barun B; Adamec I; Crnošija L; Krbot Skorić M
    Mult Scler Relat Disord; 2018 Oct; 25():99-103. PubMed ID: 30059896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome.
    van der Vuurst de Vries RM; Mescheriakova JY; Wong YYM; Runia TF; Jafari N; Samijn JP; de Beukelaar JWK; Wokke BHA; Siepman TAM; Hintzen RQ
    JAMA Neurol; 2018 Nov; 75(11):1392-1398. PubMed ID: 30083703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
    Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
    Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
    Hyun JW; Kim W; Huh SY; Park MS; Ahn SW; Cho JY; Kim BJ; Lee SH; Kim SH; Kim HJ
    Mult Scler; 2019 Oct; 25(11):1488-1495. PubMed ID: 30043667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria.
    Lo CP; Kao HW; Chen SY; Hsueh CJ; Lin WC; Hsu WL; Wu DK; Liu GC
    J Neurol Neurosurg Psychiatry; 2009 Oct; 80(10):1107-9. PubMed ID: 19546108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis.
    Alshamrani F; Alnajashi H; Almuaigel MF
    Cureus; 2020 Feb; 12(2):e6995. PubMed ID: 32206459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.